ANI Pharmaceuticals, Inc. (“ANI”) launches Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million, according to IQVIA.  
 
“This is our first generic product launch for 2020 and comes from the portfolio of commercial and pipeline drugs that we recently acquired.  The product was developed by Inventia Healthcare Limited as part of a two-drug development, manufacturing and commercialization partnership. The launch expands our commercial generic portfolio to 47 drugs,” said Arthur S. Przybyl, ANI’s President and CEO.
 
About Paliperidone Extended-Release Tablets:
 
Paliperidone Extended-Release Tablets is an atypical antipsychotic agent indicated for the treatment of schizophrenia, the treatment of schizoaffective disorder as monotherapy, and as an adjunct to mood stabilizers and/or antidepressants. For more information, including the complete list of indications and usages, please see the Full Prescribing Information.